Trial Profile
A phase I trial to evaluate mesenchymal stem cell-derived secretory factors (Sentinel)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions
- 19 Aug 2015 New trial record